» Articles » PMID: 21165233

Visual Prognosis of Retinoblastoma in the Posterior Pole Treated with Primary Chemotherapy Plus Local Treatments

Overview
Specialty Ophthalmology
Date 2010 Dec 18
PMID 21165233
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the visual outcomes of retinoblastoma in the posterior pole (RBPP) treated with chemotherapy plus local treatments and to address the prognostic factors that influence such outcomes.

Methods: The medical records of patients with RBPP diagnosed at the Department of Pediatric Ophthalmology, Seoul National University Children's Hospital between August 1987 and September 2007 were reviewed retrospectively. Only those patients treated via primary chemotherapy plus local treatments were included. The presence of foveal involvement and tumors in the posterior pole before and after treatment, the type of regression pattern and the best corrected visual acuity (BCVA) of each patient were evaluated.

Results: A total of 13 eyes in 12 patients were included. The mean final BCVA for treated RBPP was 20/210 (range, hand motion to 20/16). However, eight eyes (61.5%) had an acuity of 20/200 or better and seven eyes (53.8%) had an acuity of 20/50 or better. The mean final BCVA was significantly better in cases with negative foveal involvement; however, four eyes (37.5%) with positive foveal involvement had an acuity of 20/200 or better. Tumors area in the posterior pole and the type of regression pattern were not significantly related to final BCVA.

Conclusions: Over one half of the studied RBPP patients had working vision. Although the eyes had RBPP with positive foveal involvement, about one-third of the patients had working vision. Vision preservation should be considered when deciding on RBPP treatment.

Citing Articles

Primary Macular Retinoblastoma: Clinical Presentation and Treatment Outcomes.

Chandra K, Raval V, Reddy P V, Kaliki S J Vitreoretin Dis. 2023; 6(5):367-373.

PMID: 37006899 PMC: 9954921. DOI: 10.1177/24741264221107757.


Retinoblastoma and vision.

Warda O, Naeem Z, Roelofs K, Sagoo M, Reddy M Eye (Lond). 2022; 37(5):797-808.

PMID: 34987197 PMC: 10050411. DOI: 10.1038/s41433-021-01845-y.


Epidemiological profile of retinoblastoma in North India: Implications for primary care and family physicians.

Gupta N, Pandey A, Dimri K, Prinja S J Family Med Prim Care. 2020; 9(6):2843-2848.

PMID: 32984136 PMC: 7491789. DOI: 10.4103/jfmpc.jfmpc_265_20.


Swept-source optical coherence tomography features of regressed macular retinoblastoma.

Damodaran S, Bajaj M, Sharma P, Kumar A, Chawla R, Pujari A Indian J Ophthalmol. 2019; 67(12):2013-2018.

PMID: 31755441 PMC: 6896562. DOI: 10.4103/ijo.IJO_533_19.


Association of electroretinography with visual outcomes after ophthalmic artery chemosurgery for retinoblastoma in ICRb D and E eyes.

Levin A, Francis J, McFadden M, Brodie S, Gobin Y, Abramson D PLoS One. 2019; 14(1):e0210647.

PMID: 30650131 PMC: 6334963. DOI: 10.1371/journal.pone.0210647.


References
1.
Buckley E, Heath H . Visual acuity after successful treatment of large macular retinoblastoma. J Pediatr Ophthalmol Strabismus. 1992; 29(2):103-6. DOI: 10.3928/0191-3913-19920301-10. View

2.
Abramson D, Gerardi C, Ellsworth R, McCormick B, Sussman D, Turner L . Radiation regression patterns in treated retinoblastoma: 7 to 21 years later. J Pediatr Ophthalmol Strabismus. 1991; 28(2):108-12. DOI: 10.3928/0191-3913-19910301-12. View

3.
Holbek S, Ehlers N . Long-term visual results in eyes cured for retinoblastoma by radiation. Acta Ophthalmol (Copenh). 1989; 67(5):560-6. DOI: 10.1111/j.1755-3768.1989.tb04108.x. View

4.
Schefler A, Cicciarelli N, Feuer W, Toledano S, Murray T . Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2006; 114(1):162-9. DOI: 10.1016/j.ophtha.2006.06.042. View

5.
Shields C, Palamar M, Sharma P, Ramasubramanian A, Leahey A, Meadows A . Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol. 2009; 127(3):282-90. DOI: 10.1001/archophthalmol.2008.626. View